Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

CALR mutations are rare in childhood essential thrombocythemia.

Langabeer SE, Haslam K, McMahon C.

Pediatr Blood Cancer. 2014 Aug;61(8):1523. doi: 10.1002/pbc.24984. Epub 2014 Feb 13. No abstract available.

PMID:
24523226
2.

CALR mutations in patients with essential thrombocythemia diagnosed in childhood and adolescence.

Giona F, Teofili L, Capodimonti S, Laurino M, Martini M, Marzella D, Palumbo G, Diverio D, Foà R, Larocca LM.

Blood. 2014 Jun 5;123(23):3677-9. doi: 10.1182/blood-2014-04-572040. No abstract available.

3.

JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes.

Rumi E, Pietra D, Ferretti V, Klampfl T, Harutyunyan AS, Milosevic JD, Them NC, Berg T, Elena C, Casetti IC, Milanesi C, Sant'antonio E, Bellini M, Fugazza E, Renna MC, Boveri E, Astori C, Pascutto C, Kralovics R, Cazzola M; Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators.

Blood. 2014 Mar 6;123(10):1544-51. doi: 10.1182/blood-2013-11-539098. Epub 2013 Dec 23.

4.

Somatic mutations of calreticulin in myeloproliferative neoplasms.

Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, Them NC, Berg T, Gisslinger B, Pietra D, Chen D, Vladimer GI, Bagienski K, Milanesi C, Casetti IC, Sant'Antonio E, Ferretti V, Elena C, Schischlik F, Cleary C, Six M, Schalling M, Schönegger A, Bock C, Malcovati L, Pascutto C, Superti-Furga G, Cazzola M, Kralovics R.

N Engl J Med. 2013 Dec 19;369(25):2379-90. doi: 10.1056/NEJMoa1311347. Epub 2013 Dec 10.

5.

CALR exon 9 mutations are somatically acquired events in familial cases of essential thrombocythemia or primary myelofibrosis.

Rumi E, Harutyunyan AS, Pietra D, Milosevic JD, Casetti IC, Bellini M, Them NC, Cavalloni C, Ferretti VV, Milanesi C, Berg T, Sant'Antonio E, Boveri E, Pascutto C, Astori C, Kralovics R, Cazzola M; Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators.

Blood. 2014 Apr 10;123(15):2416-9. doi: 10.1182/blood-2014-01-550434. Epub 2014 Feb 19.

6.

Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms.

Pietra D, Rumi E, Ferretti VV, Di Buduo CA, Milanesi C, Cavalloni C, Sant'Antonio E, Abbonante V, Moccia F, Casetti IC, Bellini M, Renna MC, Roncoroni E, Fugazza E, Astori C, Boveri E, Rosti V, Barosi G, Balduini A, Cazzola M.

Leukemia. 2016 Feb;30(2):431-8. doi: 10.1038/leu.2015.277. Epub 2015 Oct 9.

7.

CALR-mutated essential thrombocythemia evolving to chronic myeloid leukemia with coexistent CALR mutation and BCR-ABL translocation.

Bonzheim I, Mankel B, Klapthor P, Schmidt J, Hinrichsen T, Wachter O, Fend F, Quintanilla-Martinez L.

Blood. 2015 Apr 2;125(14):2309-11. doi: 10.1182/blood-2014-12-616847. No abstract available.

8.

Interferon alfa therapy in CALR-mutated essential thrombocythemia.

Cassinat B, Verger E, Kiladjian JJ.

N Engl J Med. 2014 Jul 10;371(2):188-9. doi: 10.1056/NEJMc1401255. No abstract available.

PMID:
25006741
9.

CSF3R and CALR mutations in paediatric myeloid disorders and the association of CSF3R mutations with translocations, including t(8; 21).

Sano H, Ohki K, Park MJ, Shiba N, Hara Y, Sotomatsu M, Tomizawa D, Taga T, Kiyokawa N, Tawa A, Horibe K, Adachi S, Hayashi Y.

Br J Haematol. 2015 Aug;170(3):391-7. doi: 10.1111/bjh.13439. Epub 2015 Apr 9.

PMID:
25858548
10.

JAK2 V617F and CALR mutations are not mutually exclusive; findings from retrospective analysis of a small patient cohort.

McGaffin G, Harper K, Stirling D, McLintock L.

Br J Haematol. 2014 Oct;167(2):276-8. doi: 10.1111/bjh.12969. Epub 2014 Jun 17. No abstract available.

PMID:
24935260
11.

CALR versus JAK2 mutated essential thrombocythaemia - a report on 141 patients.

Trifa AP, Popp RA, Cucuianu A, Bănescu C, Tevet M, Martin B, Murat M, Vesa SC, Dima D, Cândea M, Militaru MS, Pop IV.

Br J Haematol. 2015 Jan;168(1):151-3. doi: 10.1111/bjh.13076. Epub 2014 Aug 8. No abstract available.

PMID:
25103987
12.

Distinct driver mutation profiles of childhood and adolescent essential thrombocythemia.

Langabeer SE, Haslam K, McMahon C.

Pediatr Blood Cancer. 2015 Jan;62(1):175-6. doi: 10.1002/pbc.25190. Epub 2014 Aug 17. No abstract available.

PMID:
25132652
13.

Constitutional genetic association with CALR mutations?

Eder-Azanza L, Evans P, Wickham C, Akiki S, Vizmanos JL, Chase A, Cross NC.

Leukemia. 2015 Dec;29(12):2410-1. doi: 10.1038/leu.2015.186. Epub 2015 Jul 22. No abstract available.

PMID:
26198293
14.

Novel CALR somatic mutations in essential thrombocythaemia.

Riera L, Osella-Abate S, Benevolo G, Beggiato E, Ferrero S, Pich A, Francia di Celle P.

Br J Haematol. 2016 Jun;173(5):797-801. doi: 10.1111/bjh.13638. Epub 2015 Sep 7. No abstract available.

15.

Impaired leucocyte activation is underlining the lower thrombotic risk of essential thrombocythaemia patients with CALR mutations as compared with those with the JAK2 mutation.

Torregrosa JM, Ferrer-Marín F, Lozano ML, Moreno MJ, Martinez C, Anton AI, Rivera J, Vicente V.

Br J Haematol. 2016 Mar;172(5):813-5. doi: 10.1111/bjh.13539. Epub 2015 Jun 30. No abstract available.

PMID:
26132594
16.

Endogenous megakaryocytic colonies underline association between megakaryocytes and calreticulin mutations in essential thrombocythemia.

Mondet J, Park JH, Menard A, Marzac C, Carillo S, Pourcelot E, Girodon F, Cabagnols X, Lodé L, Socoro N, Chauvet M, Bulabois CE, Cony-Makhoul P, Corm S, Cahn JY, Mossuz P.

Haematologica. 2015 May;100(5):e176-8. doi: 10.3324/haematol.2014.118927. Epub 2015 Feb 6. No abstract available.

17.

A novel somatic CALR mutation in essential thrombocythemia and effective response to interferon-alfa-2b therapy.

Zhang X, Zhang Q, Pan J.

Blood Cells Mol Dis. 2018 Nov;73:22-24. doi: 10.1016/j.bcmd.2018.08.004. Epub 2018 Aug 30. No abstract available.

PMID:
30190203
18.

Distinct molecular abnormalities underlie unique clinical features of essential thrombocythemia in children.

Fu R, Liu D, Cao Z, Zhu S, Li H, Su H, Zhang L, Xue F, Liu X, Zhang X, Cheng T, Yang R, Zhang L.

Leukemia. 2016 Mar;30(3):746-9. doi: 10.1038/leu.2015.167. Epub 2015 Jun 29. No abstract available.

19.

Differential association of calreticulin type 1 and type 2 mutations with myelofibrosis and essential thrombocytemia: relevance for disease evolution.

Cabagnols X, Defour JP, Ugo V, Ianotto JC, Mossuz P, Mondet J, Girodon F, Alexandre JH, Mansier O, Viallard JF, Lippert E, Murati A, Mozziconacci MJ, Saussoy P, Vekemans MC, Knoops L, Pasquier F, Ribrag V, Solary E, Plo I, Constantinescu SN, Casadevall N, Vainchenker W, Marzac C, Bluteau O.

Leukemia. 2015 Jan;29(1):249-52. doi: 10.1038/leu.2014.270. Epub 2014 Sep 12. No abstract available.

PMID:
25212275
20.

Analysis of calreticulin mutations in Chinese patients with essential thrombocythemia: clinical implications in diagnosis, prognosis and treatment.

Fu R, Xuan M, Zhou Y, Sun T, Bai J, Cao Z, Zhang L, Li H, Zhang D, Zhang X, Lv C, Xue F, Liu X, Yang R, Zhang L.

Leukemia. 2014 Sep;28(9):1912-4. doi: 10.1038/leu.2014.138. Epub 2014 Apr 15. No abstract available.

PMID:
24732593

Supplemental Content

Support Center